Media Contact: Alison Guzzio 484-459-3243 Alison.guzzio@thirdlaw.tech ThirdLaw Molecular has pioneered the development of Spiroligomer™ molecules – an entirely new, synthetic, therapeutic modality that reimagines molecular therapeutics Spiroligomer™ molecules combine...
ThirdLaw Molecular Inc. Launches its Groundbreaking Platform for Targeted Drug Discovery with a 4.5-Billion Molecule DNA-Encoded Library of Spiroligomer™ Macromolecules
read more